BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
307 hedge funds and large institutions have $8.41B invested in bluebird bio in 2018 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 121 increasing their positions, 88 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
1% more funds holding
Funds holding: 303 → 307 (+4)
0.11% more ownership
Funds ownership: 8.14% → 8.25% (+0.11%)
7% less capital invested
Capital invested by funds: $9B → $8.41B (-$594M)
Holders
307
Holding in Top 10
4
Calls
$237M
Puts
$142M
Top Buyers
| 1 | +$74.1M | |
| 2 | +$70.1M | |
| 3 | +$61.7M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.1M |
| 5 |
Citigroup
New York
|
+$39.3M |
Top Sellers
| 1 | -$178M | |
| 2 | -$55.1M | |
| 3 | -$49.3M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$45.2M |
| 5 |
Two Sigma Advisers
New York
|
-$42.9M |